TABLE 2.

Incidence of grade 3 or 4 of adverse events according to second‐line chemotherapy

Adverse event	FOLFIRI + Bevacizumab (N = 119)	FOLFIRI + Ramucirumab (N = 107)	FOLFIRI + Aflibercept (N = 63)	p value
Neutropenia, (%)	46 (38.7)	60 (56.1)	36 (57.1)	0.01
Febrile neutropenia, (%)	1 (0.8)	3 (2.8)	1 (1.6)	0.64
Nausea, (%)	0 (0)	1 (0.9)	3 (4.8)	0.02
Diarrhea, (%)	5 (4.2)	5 (4.7)	5 (7.9)	0.55
Hypertension, (%)	2 (1.7)	12 (11.2)	15 (23.8)	0.000007
Thromboembolic events, (%)	4 (3.4)	2 (1.9)	1 (1.6)	0.79
Proteinuria, (%)	6 (5.0)	9 (8.4)	8 (12.7)	0.18
Bleeding, (%)	0 (0)	0 (0)	2 (3.2)	0.047
Mucotitis, (%)	2 (1.7)	2 (1.9)	1 (1.6)	1
Infection, (%)	1 (0.8)	2 (1.9)	1 (1.6)	0.83
Fatigue, (%)	4 (3.4)	2 (1.9)	0 (0)	0.38
Edema, (%)	1 (0.8)	2 (1.9)	0 (0)	0.61
Renal failure, (%)	0 (0)	1 (0.9)	1 (1.6)	0.35